256 related articles for article (PubMed ID: 10197956)
1. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
De Esch IJ; Vollinga RC; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld OP; Hoffmann M; Leurs R; Menge WM; Timmerman H
J Med Chem; 1999 Apr; 42(7):1115-22. PubMed ID: 10197956
[TBL] [Abstract][Full Text] [Related]
2. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
[TBL] [Abstract][Full Text] [Related]
3. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
[TBL] [Abstract][Full Text] [Related]
4. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
6. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
[TBL] [Abstract][Full Text] [Related]
7. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
[TBL] [Abstract][Full Text] [Related]
8. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
[TBL] [Abstract][Full Text] [Related]
9. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
10. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.
Kitbunnadaj R; Zuiderveld OP; Christophe B; Hulscher S; Menge WM; Gelens E; Snip E; Bakker RA; Celanire S; Gillard M; Talaga P; Timmerman H; Leurs R
J Med Chem; 2004 May; 47(10):2414-7. PubMed ID: 15115383
[TBL] [Abstract][Full Text] [Related]
11. Effects of histamine H1-, H2- and H3-receptor selective drugs on the mechanical activity of guinea-pig small and large intestine.
Leurs R; Brozius MM; Smit MJ; Bast A; Timmerman H
Br J Pharmacol; 1991 Jan; 102(1):179-85. PubMed ID: 1646056
[TBL] [Abstract][Full Text] [Related]
12. High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models.
Tedford CE; Hoffmann M; Seyedi N; Maruyama R; Levi R; Yates SL; Ali SM; Phillips JG
Eur J Pharmacol; 1998 Jun; 351(3):307-11. PubMed ID: 9721022
[TBL] [Abstract][Full Text] [Related]
13. Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
Elz S; Kramer K; Pertz HH; Detert H; ter Laak AM; Kühne R; Schunack W
J Med Chem; 2000 Mar; 43(6):1071-84. PubMed ID: 10737740
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
Leschke C; Elz S; Garbarg M; Schunack W
J Med Chem; 1995 Apr; 38(8):1287-94. PubMed ID: 7731015
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
16. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
Sadek B; Elz S; Pertz HH; Stark H; Schunack W
Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
[TBL] [Abstract][Full Text] [Related]
17. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.
Govoni M; Bakker RA; van de Wetering I; Smit MJ; Menge WM; Timmerman H; Elz S; Schunack W; Leurs R
J Med Chem; 2003 Dec; 46(26):5812-24. PubMed ID: 14667234
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.
Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y
J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643
[TBL] [Abstract][Full Text] [Related]
20. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
Hashimoto T; Harusawa S; Araki L; Zuiderveld OP; Smit MJ; Imazu T; Takashima S; Yamamoto Y; Sakamoto Y; Kurihara T; Leurs R; Bakker RA; Yamatodani A
J Med Chem; 2003 Jul; 46(14):3162-5. PubMed ID: 12825954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
